- Home
- VICR vs KNSA Comparison
VICR vs KNSA Comparison
Compare VICR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VICR
- KNSA
- Stock Information
- Founded
- VICR 1981
- KNSA 2015
- Country
- VICR United States
- KNSA United Kingdom
- Employees
- VICR N/A
- KNSA N/A
- Industry
- VICR Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VICR Technology
- KNSA Health Care
- Exchange
- VICR Nasdaq
- KNSA Nasdaq
- Market Cap
- VICR 1.9B
- KNSA 2.1B
- IPO Year
- VICR N/A
- KNSA 2018
- Fundamental
- Price
- VICR $45.31
- KNSA $27.24
- Analyst Decision
- VICR Hold
- KNSA Strong Buy
- Analyst Count
- VICR 2
- KNSA 5
- Target Price
- VICR $43.00
- KNSA $38.80
- AVG Volume (30 Days)
- VICR 243.1K
- KNSA 1.1M
- Earning Date
- VICR 07-22-2025
- KNSA 07-22-2025
- Dividend Yield
- VICR N/A
- KNSA N/A
- EPS Growth
- VICR N/A
- KNSA N/A
- EPS
- VICR 0.51
- KNSA N/A
- Revenue
- VICR $369,154,000.00
- KNSA $481,166,000.00
- Revenue This Year
- VICR $15.61
- KNSA $37.21
- Revenue Next Year
- VICR $14.71
- KNSA $5.32
- P/E Ratio
- VICR $88.38
- KNSA N/A
- Revenue Growth
- VICR N/A
- KNSA 59.45
- 52 Week Low
- VICR $32.36
- KNSA $17.38
- 52 Week High
- VICR $65.70
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- VICR 50.75
- KNSA 45.18
- Support Level
- VICR $43.43
- KNSA $27.08
- Resistance Level
- VICR $48.10
- KNSA $28.86
- Average True Range (ATR)
- VICR 1.67
- KNSA 1.07
- MACD
- VICR 0.10
- KNSA -0.30
- Stochastic Oscillator
- VICR 47.30
- KNSA 16.87
About VICR Vicor Corporation
Vicor Corp manufactures and markets modular power components and complete power systems for converting electrical power. It provides modular power converters and configurable products, power component products and integrated circuits, and related products. Its products include Converters, Power Systems, Filters, Custom Power Systems, Input Modules, and others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.